Tofacitinib for RA Misses the Mark in Safety Study ...Middle East

Daily treatment with tofacitinib led to more malignancies and adverse cardiovascular events in older rheumatoid arthritis patients compared with treatment with a tumor necrosis factor inhibitor. Medscape Medical News

Hence then, the article about tofacitinib for ra misses the mark in safety study was published today ( Tuesday 02/02/2021 - 12:00 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tofacitinib for RA Misses the Mark in Safety Study )

Also on site :

• Teen gang member dies in custody
• Fortnite Ben 10 collaboration: Release date, what to expect & more
• Exclusive: Omni raises $120 million to fix one of AI’s biggest enterprise data problems